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The adhesion and migration properties of a cell and its interaction with stroma or other 
cells are modulated, among others, by tetraspanin proteins.1 Tetraspanin antigens are 
a family of 28 membrane proteins widely expressed in different cell types. Each cell 
type displays a specific pattern of expression of several tetraspanins that interact 
among themselves forming a tetraspanin complex. This complex forms a new type of 
membrane microdomain1, 2 that interacts with other membrane proteins, such as 
integrins, CD19, CD21, HLA-class II antigens and some growth factor receptors.2 The 
specific function of the tetraspanin proteins is not well understood, but they clearly 
modulate the biological function of the associated molecules in the complex.3 
Therefore, the pattern of expression of tetraspanin and tetraspanin-associated 
molecules can modulate the adhesion and migration characteristics of both normal and 
tumor cells. In the hematopoietic system, B-cell maturation is associated with changes 
in the pattern of expression of tetraspanins.4 Also in, B-cell malignancies, the 
tetraspanin phenotype appears to reflect the differentiation stage of the cell of origin, 
and thus can be of use in tumor phenotyping.4 
Here, we report a case of an adult female diagnosed with a biclonal B-cell 
lymphoproliferative disorder, with coexistence of B-chronic lymphocytic leukemia (B-
CLL) and splenic marginal zone B-cell lymphoma (SMZL)5 – two tumors closely related 
with respect to their B-cell maturation stage, – and attempted their discrimination by 
the determination of the pattern of tetraspanin antigen expression. For this purpose, 
five tetraspanin antigens were simultaneously analyzed. Discrimination between the 
two B-cell clones could be achieved based on conventional markers because of their 
different reactivity for CD5 and CD19 (B-CLL cells were CD5+/CD19dim and SMZL cells 
were CD5-/CD19++) as illustrated in Figure 1 (panel b). The following tetraspanin 
antigens were studied: CD37 (B-cell specific), CD53 (restricted to lymphoid-myeloid 
lineages), CD9 and CD81 (expressed in most cell types, including hematopoietic and 
epithelial cells), and CD63 (mostly present in endosomes). In addition, the reactivity 
for the CD19, CD21 and HLA-DR tetraspanin-associated molecules was determined by 
multicolor flow cytometry, as previously described.5 
 
 
 
 
 
 
Figure 1. 
 
Illustrative bivariate dot plots of a peripheral blood (PB) sample from a patient with 
two distinct neoplastic B-cell clones, one corresponding to a CD19+/CD5+ B-cell 
chronic lymphocytic leukemia (red dots, with lower light scatter characteristics) and 
the other to a CD19++/CD5- splenic marginal zone lymphoma (blue dots) top right 
and middle. Note that clearly different patterns of expression for the CD53 (top 
right), CD81 (bottom left), CD37 (bottom middle) and CD19 (bottom right) antigens 
were observed in each of the two B-cell clones. Immunophenotypic studies were 
performed on erythrocyte-lysed (PB) samples using well-established stain, lyse and 
then wash procedures.8 Finally, cells were resuspended in 0.5 ml of PBS and 
analyzed in a FACSCalibur flow cytometer using the CellQuest software program 
(BDB). The source of the MoAb was as follows: CD19, CD38 and anti-HLA-DR were 
purchased from Becton Dickinson Biosciences (–BDB- San José, CA, USA), CD53 and 
CD81 were from PharMingen (San Diego, CA), CD9 and CD63 from Immunotech 
(Marseille, France), CD21 from DakoCytomation (Glostrup, Denmark) and CD37 
from DIATEC.com AS (Oslo, Norway). 
Full figure and legend (207K)  
 
 
Interestingly, the two distinct B-cell clones showed a different pattern of expression of 
several tetraspanin antigens and tetraspanin-associated molecules (Figure 1). 
Accordingly, three of the five tetraspanin antigens studied (CD53, CD81 and CD37) 
could be used to clearly discriminate between the two clonal B-cell populations in a 
similar way to the CD19 and CD5 markers, especially if the CD53/CD81 and 
CD37/CD81 combinations were used in double-staining with different fluorochomes; B-
CLL cells were CD53-, CD81+ and CD37- while SMZL cells were CD53+, CD81- and 
CD37+. In turn, the CD19 tetraspanin-associated molecule was also differentially 
expressed by the two distinct B-cell clones, while CD21 and HLADR could not be used 
to discriminate between the two tumor clones. It should be noted that in B cells, CD19 
forms part of a signaling complex of which tetraspanins are a major component; 
however, until now such complexes have been characterized only for CD816 and CD81 
forms complexes with other tetraspanins.1, 2 The varying composition of the 
tetraspanins-CD19-CD21 complexes on the two neoplastic B-cell populations suggests 
that the complex composition, and therefore the signaling, are different in each of the 
two coexisting B-cell clones.7 Functionally, it is interesting to note that CD53 is an 
antigen whose engagement protects cells from apoptosis, and thus could be related to 
the prolonged survival of B-CLL, but not SMZL, neoplastic B-cells.3 In addition, the 
observation of the existence of a different pattern of tetraspanin expression could also 
reflect the existence of different adhesion properties for each tumor cell population, 
and thus affect their migration characteristics. 
From a practical point of view, our results suggest that determination of tetraspanin 
antigens can contribute to improving the characterization and discrimination of 
different B-cell malignancies, especially once diagnosis of biclonal B-
lymphoproliferative disorder is suspected. 
 
